Dx Ear: An automated tool for diagnosis of otitis media
Dx Ear: An automated tool for diagnosis of otitis media
批准号:
7908336
负责人:
JELENA KOVACEVIC
金额:
$17.28万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-05-01 至 2011-10-30
关键词:
AcuteAgeAlgorithmsAntibioticsAreaArtsCategoriesChildChild CareClassificationClinicalClinical ResearchClinical TrialsComputer softwareConsensusData SetDiagnosisDiagnosticDirect CostsEarFacilities and Administrative CostsGoalsImageImage AnalysisInfectionInflammationLiquid substanceMachine LearningMethodsOtitis MediaOtitis Media with EffusionOtoscopesPhasePhysiciansPredictive ValueProcessSchoolsSigns and SymptomsSiteSoftware ToolsSolutionsSterilitySystemTechniquesTimeTrainingTympanic membraneWorkantimicrobialantimicrobial drugbacterial resistanceclinical carediagnostic accuracydigitaldigital imagingear infectioneffusionexperienceimage processingimprovedmiddle earmultidisciplinarypoint of careprogramspublic health relevanceskillssocialsuperinfectiontooluser-friendly
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
Otitis media is a general term for middle-ear inflammation that is classified clinically as either acute otitis media (AOM) or otitis media with effusion (OME). AOM represents a bacterial super infection of the middle ear fluid and OME a sterile effusion that tends to subside spontaneously. Antibiotics are generally beneficial only for AOM. Accurate diagnosis of AOM, as well as distinction from both OME and no effusion (NOE) requires considerable training. AOM is the most common infection for which antimicrobial agents are prescribed for children in the US. By age seven, 93 percent of children will have experienced one or more episodes of otitis media.1 AOM results in significant social burden and indirect costs due to time lost from school and work. Estimated direct costs of AOM in 1995 were $1.96 billion and indirect costs were estimated to be $1.02 billion, with a total of 20 million prescriptions for antimicrobials related to otitis media.2 Given these considerations, our goal is to: Develop a software tool to classify images into one of three stringent clinical diagnostic categories (AOM/OME/NOE), and validate the algorithm on tympanic membrane (TM) images. We have assembled a strong multidisciplinary team that can successfully develop an automated diagnostic algorithm in this Phase-I program. We have (1) gathered a team of nationally-recognized otoscopists with substantial clinical and research experience in the context of AOM clinical trials; (2) studied the predictive value of diagnostic findings in discriminating AOM from OME from NOE; (3) acquired a large number of TM images from children; and (4) involved an internationally recognized expert in developing algorithms in all areas of image analysis and processing. In the planned Phase-II, we will use the algorithm developed in the Phase-I program and incorporate it into a user-friendly and marketable digital otoscope-software platform that can be used at the point-of-care by clinicians to improve the care of children with this frequently occurring condition. This will be followed by a clinical trial evaluating its immediate impact on clinical care, and, in particular, utilization of antimicrobials. Our main goal will be to develop an accurate automated algorithm for classifying the three diagnostic categories (AOM/OME/NOE). We aim to achieve an overall accuracy of 95 percent by applying a newly developed classification algorithm. This will include applying state-of-the-art classification methods as well as segmentation algorithms, for automated, robust diagnosis and classification of the three diagnostic categories (AOM/OME/NOE). We propose to achieve this through the following two specific aims: Specific Aim 1: Develop a robust and accurate diagnostic algorithm that can discriminate TM digital images into 1of 3 stringent diagnostic categories (AOM/OME/NOE). Specific Aim 2: Validate the algorithm on a dataset that includes over 2000 TM images collected in a recently completed NIAID-sponsored clinical trial.
PUBLIC HEALTH RELEVANCE:
AOM is the most common infection for which antimicrobial agents are prescribed in children in the US. By age seven, 93 percent of children will have experienced one or more episodes of otitis media. AOM results in significant social burden and indirect costs due to time lost from school and work. Estimated direct costs of AOM in 1995 were $1.96 billion and indirect costs were estimated to be $1.02 billion, with a total of 20 million prescriptions for antimicrobials related to otitis media. Developing an automated and accurate software tool to help classify otitis media images into one of three stringent clinical categories would have a great impact on both clinical care as well as reducing the unnecessary prescriptions of antibiotics in the US.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
IEEE International Symposium on Biomedical Imaging (ISBI) 2015
-
批准号:8911701
-
项目类别:
-
资助金额:$2.2万
-
财政年份:2015
-
负责人:JELENA KOVACEVIC
-
依托单位:
Algorithms and Image Analysis Software Tool for Automated Recognition and Identif
-
批准号:7901383
-
项目类别:
-
资助金额:$7.03万
-
财政年份:2009
-
负责人:JELENA KOVACEVIC
-
依托单位:
Algorithms and Image Analysis Software Tool for Automated Recognition and Identif
-
批准号:7712998
-
项目类别:
-
资助金额:$7.04万
-
财政年份:2009
-
负责人:JELENA KOVACEVIC
-
依托单位:
AUTOMATED SEGMENTATION OF FLUORESCENCE MICROSCOPY DATA SETS
-
批准号:7513584
-
项目类别:
-
资助金额:$6.93万
-
财政年份:2008
-
负责人:JELENA KOVACEVIC
-
依托单位:
AUTOMATED SEGMENTATION OF FLUORESCENCE MICROSCOPY DATA SETS
-
批准号:7632204
-
项目类别:
-
资助金额:$6.99万
-
财政年份:2008
-
负责人:JELENA KOVACEVIC
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: